awmsg logo



cinacalcet (Mimpara™)


Reference No. 3294

Publication date:
29/11/2017


Appraisal information

cinacalcet (Mimpara™) 30 mg film-coated tablet
cinacalcet (Mimpara™) 60 mg film-coated tablet
cinacalcet (Mimpara™) 90 mg film-coated tablet
cinacalcet (Mimpara™) 1 mg granules
cinacalcet (Mimpara™) 5 mg granules
cinacalcet (Mimpara™) 2.5 mg granules


Company: Amgen Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/11/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, cinacalcet (Mimpara™) cannot be endorsed for use within NHS Wales for the treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.
Statement of Advice (SOA)
Download